
Mark Schiffman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4609927/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The development of "automated visual evaluation―for cervical cancer screening: The promise and challenges in adapting deepâ€learning for clinical testing. International Journal of Cancer, 2022, 150, 741-752.	2.3	29
2	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. Journal of the National Cancer Institute, 2022, 114, 845-853.	3.0	12
3	The IARC Perspective on Cervical Cancer Screening. Obstetrical and Gynecological Survey, 2022, 77, 154-156.	0.2	1
4	Different human papillomavirus types share early natural history transitions in immunocompetent women. International Journal of Cancer, 2022, 151, 920-929.	2.3	5
5	Redesign of a rapid, lowâ€cost <scp>HPV</scp> typing assay to support riskâ€based cervical screening and management. International Journal of Cancer, 2022, 151, 1142-1149.	2.3	12
6	Accuracy and Efficiency of Deep-Learning–Based Automation of Dual Stain Cytology in Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 72-79.	3.0	82
7	The Orderly Incorporation of Continuing Technologic Advances Into Cervical Cancer Screening. Journal of the National Cancer Institute, 2021, 113, 231-233.	3.0	3
8	Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017. American Journal of Obstetrics and Gynecology, 2021, 224, 366.e1-366.e32.	0.7	14
9	Efficacy of ASO4-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study. Journal of Infectious Diseases, 2021, 223, 1576-1581.	1.9	7
10	Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016–2020. Journal of Women's Health, 2021, 30, 5-13.	1.5	31
11	Cervical Screening Performance. American Journal of Clinical Pathology, 2021, 155, 616-620.	0.4	3
12	Deep Metric Learning for Cervical Image Classification. IEEE Access, 2021, 9, 53266-53275.	2.6	25
13	A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. Preventive Medicine, 2021, 144, 106438.	1.6	20
14	Network Visualization and Pyramidal Feature Comparison for Ablative Treatability Classification Using Digitized Cervix Images. Journal of Clinical Medicine, 2021, 10, 953.	1.0	7
15	The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses. Gynecologic Oncology, 2021, 161, 297-303.	0.6	3
16	A Deep Clustering Method For Analyzing Uterine Cervix Images Across Imaging Devices. , 2021, 2021, 527-532.		4
17	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. International Journal of Molecular Sciences, 2021, 22, 6463.	1.8	9
18	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses, 2021, 13, 1948.	1.5	7

#	Article	IF	CITATIONS
19	Deep multiple-instance learning for abnormal cell detection in cervical histopathology images. Computers in Biology and Medicine, 2021, 138, 104890.	3.9	18
20	STRIDES - STudying Risk to Improve DisparitiES in Cervical Cancer in Mississippi – Design and baseline results of a Statewide Cohort Study. Preventive Medicine, 2021, 153, 106740.	1.6	9
21	Risk Factors for Non–Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA–Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine Trial. Journal of Infectious Diseases, 2021, 224, 503-516.	1.9	4
22	Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies. Cancer Prevention Research, 2021, 14, 919-926.	0.7	5
23	Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city—Lessons learned from the Amazon city of Manaus, Brazil. PLoS ONE, 2021, 16, e0258539.	1.1	3
24	Development of a Large Biorepository of Cervical Specimens for theImproving Risk Informed HPV Screening Study (IRIS). Journal of Clinical Virology, 2021, 145, 105014.	1.6	2
25	Ageâ€specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi. Cancer Medicine, 2021, 10, 8641-8650.	1.3	9
26	The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine, 2021, 385, 1908-1918.	13.9	125
27	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0865.2021.	1.1	3
28	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. International Journal of Cancer, 2020, 146, 617-626.	2.3	5
29	Response to Pretorius and Belinson. Journal of the National Cancer Institute, 2020, 112, 115-116.	3.0	0
30	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. Journal of the National Cancer Institute, 2020, 112, 818-828.	3.0	19
31	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. Archives of Pathology and Laboratory Medicine, 2020, 144, 725-734.	1.2	30
32	The Natural History of Human Papillomavirus Infection in Relation to Cervical Cancer. , 2020, , 149-160.		4
33	Response to Letter to the Editor Regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2020, 24, 426-426.	0.9	6
34	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infectious Agents and Cancer, 2020, 15, 60.	1.2	27
35	Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing. Infectious Agents and Cancer, 2020, 15, 61.	1.2	24
36	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine, 2020, 22, 100293.	3.2	109

#	Article	IF	CITATIONS
37	Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncology, The, 2020, 21, 1643-1652.	5.1	54
38	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus–positive and -Negative Cervical Precancers. Cancer Prevention Research, 2020, 13, 829-840.	0.7	6
39	A rapid, high-volume cervical screening project using self-sampling and isothermal PCR HPV testing. Infectious Agents and Cancer, 2020, 15, 64.	1.2	11
40	Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening. Infectious Agents and Cancer, 2020, 15, 65.	1.2	19
41	A demonstration of automated visual evaluation of cervical images taken with a smartphone camera. International Journal of Cancer, 2020, 147, 2416-2423.	2.3	46
42	Generalized integration model for improved statistical inference by leveraging external summary data. Biometrika, 2020, 107, 689-703.	1.3	26
43	Challenges Associated With Cervical Cancer Screening and Management in Obese Women. Journal of Lower Genital Tract Disease, 2020, 24, 184-191.	0.9	9
44	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viralâ€host interaction with implications for disease intervention. International Journal of Cancer, 2020, 147, 2677-2686.	2.3	44
45	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15â€year cervical cancer screening experience at Kaiser Permanente Northern California. International Journal of Cancer, 2020, 147, 1612-1620.	2.3	15
46	Cervicovaginal microbiome and natural history of HPVÂin a longitudinal study. PLoS Pathogens, 2020, 16, e1008376.	2.1	150
47	Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix. Cancer Cytopathology, 2020, 128, 528-534.	1.4	12
48	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2020, 24, 102-131.	0.9	608
49	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 132-143.	0.9	116
50	The D2 and D3 Sublineages of Human Papilloma Virus 16–Positive Cervical Cancer in Guatemala Differ in Integration Rate and Age of Diagnosis. Cancer Research, 2020, 80, 3803-3809.	0.4	8
51	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. JAMA Oncology, 2020, 6, 696.	3.4	18
52	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nature Communications, 2020, 11, 886.	5.8	52
53	Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial. Journal of the National Cancer Institute, 2020, 112, 1030-1037.	3.0	42
54	Identification of HPV genotypes causing cervical precancer using tissueâ€based genotyping. International Journal of Cancer, 2020, 146, 2836-2844.	2.3	13

#	Article	IF	CITATIONS
55	2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 90-101.	0.9	66
56	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 144-147.	0.9	48
57	An Introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. Journal of Lower Genital Tract Disease, 2020, 24, 87-89.	0.9	26
58	Viral coinfection analysis using a MinHash toolkit. BMC Bioinformatics, 2019, 20, 389.	1.2	3
59	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. Journal of Infectious Diseases, 2019, 220, 1609-1619.	1.9	17
60	Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1388-1394.	1.1	2
61	Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. JAMA Internal Medicine, 2019, 179, 881.	2.6	98
62	False positive cervical HPV screening test results. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 184-187.	4.5	31
63	Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing. Journal of Clinical Microbiology, 2019, 57, .	1.8	27
64	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Research (Amsterdam,) Tj ETQq0 0 0 rgBT	/Owerlock	e 1 0 87f 50 372
65	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. Journal of the National Cancer Institute, 2019, 111, 923-932.	3.0	249
66	Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. JAMA Oncology, 2019, 5, 181.	3.4	79
67	Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Preventive Medicine, 2019, 118, 44-50.	1.6	21
68	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. Journal of Clinical Microbiology, 2018, 56, .	1.8	18
69	A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations. Preventive Medicine, 2018, 110, 100-105.	1.6	9
70	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. Journal of the National Cancer Institute, 2018, 110, 1222-1228.	3.0	12
71	Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years. Cancer Prevention Research, 2018, 11, 165-170.	0.7	26
72	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. Journal of the National Cancer Institute, 2018, 110, 501-508.	3.0	116

#	Article	IF	CITATIONS
73	Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women. Clinical Cancer Research, 2018, 24, 2194-2202.	3.2	75
74	Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. Preventive Medicine, 2018, 109, 44-50.	1.6	14
75	Accelerating cervical cancer control and prevention. Lancet Public Health, The, 2018, 3, e6-e7.	4.7	13
76	Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61). Virology, 2018, 516, 86-101.	1.1	35
77	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. Preventive Medicine, 2018, 111, 429-435.	1.6	15
78	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. Journal of Lower Genital Tract Disease, 2018, 22, 97-103.	0.9	5
79	A prospective study of risk-based colposcopy demonstrates improved detection of cervicalÂprecancers. American Journal of Obstetrics and Gynecology, 2018, 218, 604.e1-604.e8.	0.7	23
80	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. Journal of Clinical Oncology, 2018, 36, 1184-1191.	0.8	65
81	Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala. BMC Cancer, 2018, 18, 562.	1.1	9
82	Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathogens, 2018, 14, e1007352.	2.1	77
83	Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. Cancer Cytopathology, 2018, 126, 950-958.	1.4	12
84	Risk of Cervical Intraepithelial Neoplasia 2 or Worse by Cytology, Human Papillomavirus 16/18, and Colposcopy Impression. Obstetrics and Gynecology, 2018, 132, 725-735.	1.2	25
85	ls It Time to Move Beyond Visual Inspection With Acetic Acid for Cervical Cancer Screening?. Global Health, Science and Practice, 2018, 6, 242-246.	0.6	27
86	The next generation of cervical cancer screening programs: Making the case for risk-based guidelines. Current Problems in Cancer, 2018, 42, 521-526.	1.0	5
87	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. Annals of Internal Medicine, 2018, 168, 20.	2.0	50
88	How confident can we be in the current guidelines for exiting cervical screening?. Preventive Medicine, 2018, 114, 188-192.	1.6	27
89	An Introduction to the New Journal Forum. Journal of Lower Genital Tract Disease, 2018, 22, 89-90.	0.9	Ο
90	T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. PLoS ONE, 2018, 13, e0178167.	1.1	14

#	Article	IF	CITATIONS
91	Control of HPV-associated cancers with HPV vaccination. Lancet Infectious Diseases, The, 2017, 17, 6-8.	4.6	6
92	Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18‥ear followâ€up of the Guanacaste cohort. International Journal of Cancer, 2017, 140, 1926-1934.	2.3	10
93	Cervical cancer screening: Epidemiology as the necessary but not sufficient basis of public health practice. Preventive Medicine, 2017, 98, 3-4.	1.6	31
94	Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. International Journal of Cancer, 2017, 141, 701-710.	2.3	62
95	Trends in cervical cancer incidence in younger US women from 2000 to 2013. Gynecologic Oncology, 2017, 144, 391-395.	0.6	10
96	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute, 2017, 109, djw300.	3.0	43
97	Assessment of a New Lower-Cost Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus: Useful for Cervical Screening in Limited-Resource Settings?. Journal of Clinical Microbiology, 2017, 55, 2348-2355.	1.8	10
98	Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 87-90.	0.9	23
99	In response to: Human papillomavirus screening for low and middle-income countries. Preventive Medicine, 2017, 100, 297-298.	1.6	2
100	Typeâ€dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18. International Journal of Cancer, 2017, 140, 1747-1756.	2.3	30
101	Flexible risk prediction models for left or interval-censored data from electronic health records. Annals of Applied Statistics, 2017, 11, 1063-1084.	0.5	15
102	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. Journal of Lower Genital Tract Disease, 2017, 21, 230-234.	0.9	56
103	ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic Practice. Journal of Lower Genital Tract Disease, 2017, 21, 223-229.	0.9	87
104	Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines. Journal of Lower Genital Tract Disease, 2017, 21, 261-267.	0.9	55
105	Smoking and subsequent human papillomavirus infection: a mediation analysis. Annals of Epidemiology, 2017, 27, 724-730.e1.	0.9	33
106	Effective use of human papillomavirus testing for cervical cancer screening requires extended intervals to target persistent infections and precancerous lesions. Preventive Medicine, 2017, 105, 378-380.	1.6	3
107	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell, 2017, 170, 1164-1174.e6.	13.5	221
108	Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology. Obstetrics and Gynecology, 2017, 130, 1218-1225.	1.2	35

#	Article	IF	CITATIONS
109	Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records. Statistics in Medicine, 2017, 36, 3583-3595.	0.8	25
110	Why does cervical cancer occur in a state-of-the-art screening program?. Gynecologic Oncology, 2017, 146, 546-553.	0.6	47
111	Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2. International Journal of Cancer, 2017, 140, 718-725.	2.3	19
112	Distribution of cell types differs in Papanicolaou tests of squamous cell carcinomas and adenocarcinomas. Journal of the American Society of Cytopathology, 2017, 6, 10-15.	0.2	3
113	Reply to Letter: Using novel risk stratification statistics to better understand the value of screening tests. International Journal of Cancer, 2016, 139, 1669-1669.	2.3	0
114	Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images. Journal of Lower Genital Tract Disease, 2016, 20, 154-161.	0.9	20
115	A Suggested Approach to Simplify and Improve Cervical Screening in the United States. Journal of Lower Genital Tract Disease, 2016, 20, 1-7.	0.9	37
116	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. Obstetrics and Gynecology, 2016, 128, 1248-1257.	1.2	22
117	Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers, 2016, 2, 16086.	18.1	615
118	Response. Journal of the National Cancer Institute, 2016, 108, djv390.	3.0	0
119	HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. Journal of the National Cancer Institute, 2016, 108, djw100.	3.0	147
120	The population impact of human papillomavirus/cytology cervical cotesting at 3â€year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. Cancer, 2016, 122, 3682-3686.	2.0	15
121	Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1449-1455.	1.1	43
122	A cohort study of cervical screening using partial HPV typing and cytology triage. International Journal of Cancer, 2016, 139, 2606-2615.	2.3	68
123	Risk assessment to guide cervical screening strategies in a large <scp>C</scp> hinese population. International Journal of Cancer, 2016, 138, 2639-2647.	2.3	16
124	Variantâ€specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia. International Journal of Cancer, 2016, 139, 1098-1105.	2.3	17
125	Sholom Wacholder: In Memoriam (1955–2015). Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 229-230.	1.1	0
126	Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology, 2016, 76, S49-S55.	1.6	236

#	Article	IF	CITATIONS
127	Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. American Journal of Obstetrics and Gynecology, 2016, 215, 212.e1-212.e15.	0.7	108
128	Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. Carcinogenesis, 2016, 37, 188-196.	1.3	41
129	Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. Journal of Infectious Diseases, 2016, 213, 939-947.	1.9	18
130	Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 36-42.	1.1	14
131	Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection. Journal of the National Cancer Institute, 2016, 108, djv302.	3.0	92
132	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infectious Diseases, 2015, 15, 544.	1.3	40
133	Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening. Obstetrics and Gynecology, 2015, 125, 330-337.	1.2	188
134	Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era. Ecancermedicalscience, 2015, 9, 530.	0.6	17
135	HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study. Gynecologic Oncology, 2015, 138, 94-100.	0.6	10
136	Efficacy of fewer than three doses of an HPV-16/18 ASO4-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncology, The, 2015, 16, 775-786.	5.1	247
137	Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial. BMJ, The, 2015, 351, h4358.	3.0	32
138	Transitioning to a new era in cervical cancer screening. Gynecologic Oncology, 2015, 136, 175-177.	0.6	8
139	Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. Gynecologic Oncology, 2015, 136, 178-182.	0.6	374
140	HPV16 methylâ€haplotypes determined by a novel nextâ€generation sequencing method are associated with cervical precancer. International Journal of Cancer, 2015, 136, E146-53.	2.3	31
141	Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 3-11.	4.5	75
142	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecologic Oncology, 2015, 138, 573-578.	0.6	49
143	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1304-1310.	1.1	44
144	Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine, 2015, 33, 2141-2151.	1.7	17

#	Article	IF	CITATIONS
145	Towards therapeutic vaccination against cervical precancer?. Lancet, The, 2015, 386, 2036-2038.	6.3	1
146	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3255-64.	3.3	197
147	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. Journal of the National Cancer Institute, 2015, 107, djv257.	3.0	130
148	Ageâ€stratified 5â€year risks of cervical precancer among women with enrollment and newly detected <scp>HPV</scp> infection. International Journal of Cancer, 2015, 136, 1665-1671.	2.3	39
149	Association of Human Papillomavirus 31 DNA Load with Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3. Journal of Clinical Microbiology, 2015, 53, 3451-3457.	1.8	4
150	A Study of Genotyping for Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results. Journal of Clinical Microbiology, 2015, 53, 52-59.	1.8	89
151	Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. Journal of Clinical Oncology, 2015, 33, 83-89.	0.8	156
152	Risk Assessment Approach to Management. , 2015, , 305-313.		3
153	The low risk of precancer after a screening result of human papillomavirusâ€negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathology, 2014, 122, 842-850.	1.4	25
154	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. Journal of the National Cancer Institute, 2014, 107, dju400-dju400.	3.0	24
155	Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays. Frontiers in Oncology, 2014, 3, 328.	1.3	24
156	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. Journal of the National Cancer Institute, 2014, 106, dju153-dju153.	3.0	200
157	Response. Journal of the National Cancer Institute, 2014, 107, dju390-dju390.	3.0	Ο
158	Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. Journal of Infectious Diseases, 2014, 210, 448-455.	1.9	33
159	No Evidence for Synergy Between Human Papillomavirus Genotypes for the Risk of High-Grade Squamous Intraepithelial Lesions in a Large Population-Based Study. Journal of Infectious Diseases, 2014, 209, 855-864.	1.9	46
160	Comparison of Human Papillomavirus Detections in Urine, Vulvar, and Cervical Samples from Women Attending a Colposcopy Clinic. Journal of Clinical Microbiology, 2014, 52, 187-192.	1.8	37
161	An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters. American Journal of Epidemiology, 2014, 180, 545-555.	1.6	87
162	Evaluation of a multiplex panel of immuneâ€related markers in cervical secretions: A methodologic study. International Journal of Cancer, 2014, 134, 411-425.	2.3	18

#	Article	IF	CITATIONS
163	Lineages of Oncogenic Human Papillomavirus Types Other Than Type 16 and 18 and Risk for Cervical Intraepithelial Neoplasia. Journal of the National Cancer Institute, 2014, 106, .	3.0	38
164	Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates. American Journal of Epidemiology, 2014, 180, 599-607.	1.6	14
165	Filling a gap in cervical cancer screening programmes. Lancet Oncology, The, 2014, 15, 249-251.	5.1	18
166	Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. Cancer Cytopathology, 2014, 122, 694-701.	1.4	14
167	Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. Journal of Clinical Virology, 2014, 60, 414-417.	1.6	18
168	Interobserver reproducibility and accuracy of p16/ <scp>K</scp> iâ€67 dualâ€stain cytology in cervical cancer screening. Cancer Cytopathology, 2014, 122, 914-920.	1.4	51
169	Heterogeneity of highâ€grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management. International Journal of Cancer, 2013, 132, 148-154.	2.3	28
170	Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage. International Journal of Cancer, 2013, 132, 549-555.	2.3	19
171	Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: A search for human papillomavirus. International Journal of Cancer, 2013, 133, 1513-1515.	2.3	63
172	The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecologic Oncology, 2013, 128, 265-270.	0.6	105
173	Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 553-560.	1.1	223
174	A study of borderline positive Hybrid Capture 2 tests in the Kaiser Permanente Northern California cervical screening program: Evidence against retesting. Journal of Virological Methods, 2013, 189, 77-79.	1.0	1
175	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, H1-H31.	1.7	272
176	Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment. American Journal of Epidemiology, 2013, 178, 752-760.	1.6	26
177	Risk of Precancer Determined by HPV Genotype Combinations in Women with Minor Cytologic Abnormalities. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1095-1101.	1.1	24
178	Cervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting. New England Journal of Medicine, 2013, 369, 2324-2331.	13.9	102
179	Intratypic variants of human papillomavirus type 16 and risk of cervical Neoplasia in Taiwan. Journal of Medical Virology, 2013, 85, 1567-1576.	2.5	19
180	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6021-6026.	3.3	1,202

#	Article	IF	CITATIONS
181	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	1.7	40
182	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	1.7	33
183	Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. Gynecologic Oncology, 2013, 130, 595-600.	0.6	24
184	Natural immune responses against eight oncogenic human papillomaviruses in the ASCUSâ€LSIL Triage Study. International Journal of Cancer, 2013, 133, 2172-2181.	2.3	16
185	Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. International Journal of Cancer, 2013, 132, 1412-1422.	2.3	123
186	Benchmarking CIN 3+ Risk as the Basis for Incorporating HPV and Pap Cotesting into Cervical Screening and Management Guidelines. Journal of Lower Genital Tract Disease, 2013, 17, S28-S35.	0.9	167
187	Five-Year Risks of CIN 2+ and CIN 3+ Among Women With HPV-Positive and HPV-Negative LSIL Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S43-S49.	0.9	49
188	Five-Year Risks of CIN 3+ and Cervical Cancer Among WomenWho Test Pap-Negative But Are HPV-Positive. Journal of Lower Genital Tract Disease, 2013, 17, S56-S63.	0.9	73
189	Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses. Human Vaccines and Immunotherapeutics, 2013, 9, 1399-1406.	1.4	35
190	Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS. Journal of Lower Genital Tract Disease, 2013, 17, S78-S84.	0.9	75
191	Follow-up Testing After Colposcopy. Journal of Lower Genital Tract Disease, 2013, 17, S69-S77.	0.9	59
192	Five-Year Risk of CIN 3+ to Guide the Management of Women Aged 21 to 24 Years. Journal of Lower Genital Tract Disease, 2013, 17, S64-S68.	0.9	28
193	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease, 2013, 17, S1-S27.	0.9	614
194	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV Testing of ASC-US Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S36-S42.	0.9	85
195	Reproducibility of Linear Array for Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2013, 51, 625-628.	1.8	9
196	Cervical Histopathology Variability Among Laboratories: A Population-Based Statewide Investigation. American Journal of Clinical Pathology, 2013, 139, 330-335.	0.4	28
197	Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer Prevention Research, 2013, 6, 1242-1250.	0.7	185
198	Five-Year Risks of CIN 3+ and Cervical Cancer Among Women With HPV-Positive and HPV-Negative High-Grade Pap Results. Journal of Lower Genital Tract Disease, 2013, 17, S50-S55.	0.9	59

#	Article	IF	CITATIONS
199	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Obstetrics and Gynecology, 2013, 121, 829-846.	1.2	617
200	HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays. PLoS ONE, 2013, 8, e53067.	1.1	39
201	Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS ONE, 2013, 8, e68329.	1.1	387
202	Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. PLoS ONE, 2013, 8, e72565.	1.1	47
203	Longitudinal Analysis of Carcinogenic Human Papillomavirus Infection and Associated Cytologic Abnormalities in the Guanacaste Natural History Study: Looking Ahead to Cotesting. Journal of Infectious Diseases, 2012, 205, 498-505.	1.9	5
204	Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. Journal of the National Cancer Institute, 2012, 104, 1738-1749.	3.0	119
205	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 2012, 137, 516-542.	0.4	686
206	Methylation of Human Papillomavirus Type 16 Genome and Risk of Cervical Precancer in a Costa Rican Population. Journal of the National Cancer Institute, 2012, 104, 556-565.	3.0	99
207	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Journal of Lower Genital Tract Disease, 2012, 16, 175-204.	0.9	310
208	Evaluation of Any or Type-Specific Persistence of High-Risk Human Papillomavirus for Detecting Cervical Precancer. Journal of Clinical Microbiology, 2012, 50, 300-306.	1.8	18
209	Direct Comparison of HPV16 Serological Assays Used to Define HPV-NaÃ ⁻ ve Women in HPV Vaccine Trials. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1547-1554.	1.1	24
210	Policy Implications of Adjusting Randomized Trial Data for Economic Evaluations. Medical Decision Making, 2012, 32, 400-427.	1.2	3
211	Human Papillomavirus Load Measured by Linear Array Correlates with Quantitative PCR in Cervical Cytology Specimens. Journal of Clinical Microbiology, 2012, 50, 1564-1570.	1.8	26
212	Success of HPV vaccination is now a matter of coverage. Lancet Oncology, The, 2012, 13, 10-12.	5.1	35
213	Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population. Clinical Cancer Research, 2012, 18, 4154-4162.	3.2	196
214	Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2125-2137.	1.1	143
215	A Descriptive Analysis of Prevalent vs Incident Cervical Intraepithelial Neoplasia Grade 3 Following Minor Cytologic Abnormalities. American Journal of Clinical Pathology, 2012, 138, 241-246.	0.4	7
216	Updating the Natural History of Human Papillomavirus and Anogenital Cancers. Vaccine, 2012, 30, F24-F33.	1.7	303

#	Article	IF	CITATIONS
217	Comparison of the cobas Human Papillomavirus (HPV) Test with the Hybrid Capture 2 and Linear Array HPV DNA Tests. Journal of Clinical Microbiology, 2012, 50, 61-65.	1.8	47
218	Clinical and Pathological Heterogeneity of Cervical Intraepithelial Neoplasia Grade 3. PLoS ONE, 2012, 7, e29051.	1.1	13
219	Longâ€ŧerm risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. International Journal of Cancer, 2012, 131, 211-218.	2.3	29
220	Low risk of typeâ€specific carcinogenic HPV reâ€appearance with subsequent cervical intraepithelial neoplasia grade 2/3. International Journal of Cancer, 2012, 131, 1874-1881.	2.3	29
221	Association of human papillomavirus type 31 variants with risk of cervical intraepithelial neoplasia grades 2–3. International Journal of Cancer, 2012, 131, 2300-2307.	2.3	28
222	Molecular mapping of highâ€grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. International Journal of Cancer, 2012, 131, E946-53.	2.3	54
223	Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. International Journal of Cancer, 2012, 131, 2903-2909.	2.3	51
224	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Ca-A Cancer Journal for Clinicians, 2012, 62, 147-172.	157.7	1,022
225	Switch from cytologyâ€based to human papillomavirus testâ€based cervical screening: Implications for colposcopy. International Journal of Cancer, 2012, 130, 1879-1887.	2.3	18
226	The ageâ€specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screenâ€andâ€treat strategies. International Journal of Cancer, 2012, 130, 2111-2117.	2.3	50
227	Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer. PLoS ONE, 2012, 7, e33619.	1.1	37
228	The Cervical Microbiome over 7 Years and a Comparison of Methodologies for Its Characterization. PLoS ONE, 2012, 7, e40425.	1.1	101
229	The HPV Status of Patients with Fanconi Anemia Blood, 2012, 120, 2362-2362.	0.6	0
230	Long-Term Persistence of Prevalently Detected Human Papillomavirus Infections in the Absence of Detectable Cervical Precancer and Cancer. Journal of Infectious Diseases, 2011, 203, 814-822.	1.9	47
231	Human Papillomavirus Testing in the Prevention of Cervical Cancer. Journal of the National Cancer Institute, 2011, 103, 368-383.	3.0	583
232	Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology, The, 2011, 12, 663-672.	5.1	504
233	Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncology, The, 2011, 12, 862-870.	5.1	168
234	Premature conclusions on HPV-only testing – Authors' reply. Lancet Oncology, The, 2011, 12, 993.	5.1	2

#	Article	IF	CITATIONS
235	Accepting the Universal Truths of Cervical Human Papillomavirus Epidemiology in Pursuit of the Remaining Mysteries. Sexually Transmitted Diseases, 2011, 38, 907-908.	0.8	1
236	Evaluation of the Polyclonal ELISA HPV Serology Assay as a Biomarker for Human Papillomavirus Exposure. Sexually Transmitted Diseases, 2011, 38, 976-982.	0.8	18
237	The Clinical Meaning of a Cervical Intraepithelial Neoplasia Grade 1 Biopsy. Obstetrics and Gynecology, 2011, 118, 1222-1229.	1.2	35
238	A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. Infectious Agents and Cancer, 2011, 6, 12.	1.2	23
239	HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. Infectious Agents and Cancer, 2011, 6, 19.	1.2	25
240	Alterations of T ell surface markers in older women with persistent human papillomavirus infection. International Journal of Cancer, 2011, 128, 597-607.	2.3	7
241	Prevalence of genotypeâ€specific human papillomavirus infection and cervical neoplasia in Taiwan: A communityâ€based survey of 10,602 women. International Journal of Cancer, 2011, 128, 1192-1203.	2.3	29
242	Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine. Journal of the National Cancer Institute, 2011, 103, 1444-1451.	3.0	274
243	Clustering of Multiple Human Papillomavirus Infections in Women From a Population-Based Study in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2011, 204, 385-390.	1.9	50
244	A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1398-1409.	1.1	121
245	Human Papillomavirus (HPV) Genotypes in Women with Cervical Precancer and Cancer at Kaiser Permanente Northern California. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 946-953.	1.1	66
246	Comparative Performance of Human Papillomavirus DNA Testing Using Novel Sample Collection Methods. Journal of Clinical Microbiology, 2011, 49, 4185-4189.	1.8	26
247	A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study. Journal of Infectious Diseases, 2011, 204, 94-102.	1.9	55
248	Evaluation of a New DNA Test for Detection of Carcinogenic Human Papillomavirus. Journal of Clinical Microbiology, 2011, 49, 3029-3032.	1.8	31
249	Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS ONE, 2011, 6, e20183.	1.1	137
250	Variable Risk of Cervical Precancer and Cancer After a Human Papillomavirus–Positive Test. Obstetrics and Gynecology, 2011, 117, 650-656.	1.2	13
251	Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica. Cancer Discovery, 2011, 1, 408-419.	7.7	143
252	Persistence of Type-Specific Human Papillomavirus Infection and Increased Long-term Risk of Cervical Cancer. Journal of the National Cancer Institute, 2011, 103, 1387-1396.	3.0	150

#	Article	IF	CITATIONS
253	The Oral Cavity Contains Abundant Known and Novel Human Papillomaviruses From the Betapapillomavirus and Gammapapillomavirus Genera. Journal of Infectious Diseases, 2011, 204, 787-792.	1.9	162
254	Viral Load in the Natural History of Human Papillomavirus Type 16 Infection: A Nested Case–Control Study. Journal of Infectious Diseases, 2011, 203, 1425-1433.	1.9	61
255	Persistence of Concurrent Infections with Multiple Human Papillomavirus Types: A Population-based Cohort Study. Journal of Infectious Diseases, 2011, 203, 823-827.	1.9	33
256	The Need for Forward-Looking Decision Analyses to Guide Cervical Cancer Prevention. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 219-220.	1.1	2
257	Sequence Imputation of HPV16 Genomes for Genetic Association Studies. PLoS ONE, 2011, 6, e21375.	1.1	70
258	From Human Papillomavirus to Cervical Cancer. Obstetrics and Gynecology, 2010, 116, 1221-1222.	1.2	2
259	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. Sexually Transmitted Diseases, 2010, 37, 706-714.	0.8	27
260	From Human Papillomavirus to Cervical Cancer. Obstetrics and Gynecology, 2010, 116, 177-185.	1.2	67
261	Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ: British Medical Journal, 2010, 340, c712-c712.	2.4	78
262	Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. Archives of Virology, 2010, 155, 367-370.	0.9	11
263	Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. International Journal of Cancer, 2010, 126, 684-691.	2.3	73
264	Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infectious Diseases, 2010, 10, 238.	1.3	34
265	Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer. PLoS ONE, 2010, 5, e8667.	1.1	104
266	Chlamydia trachomatis and Risk of Prevalent and Incident Cervical Premalignancy in a Population-Based Cohort. Journal of the National Cancer Institute, 2010, 102, 1794-1804.	3.0	63
267	A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. Cancer Research, 2010, 70, 3159-3169.	0.4	221
268	Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections. Journal of the National Cancer Institute, 2010, 102, 1653-1662.	3.0	155
269	Comparison of Measurements of Human Papillomavirus Persistence for Postcolposcopic Surveillance for Cervical Precancerous Lesions. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1668-1674.	1.1	20
270	Establishment and Operation of a Biorepository for Molecular Epidemiologic Studies in Costa Rica. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 916-922.	1.1	11

#	Article	IF	CITATIONS
271	Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Precancer. American Journal of Epidemiology, 2010, 171, 155-163.	1.6	26
272	Liquid-Based Cytology vs Conventional Cytology in Detecting Cervical Cancer—Reply. JAMA - Journal of the American Medical Association, 2010, 303, 1034.	3.8	0
273	Human Papillomavirus Genotypes in Cervical Intraepithelial Neoplasia Grade 3. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1675-1681.	1.1	43
274	Hierarchical Clustering of Human Papilloma Virus Genotype Patterns in the ASCUS-LSIL Triage Study. Cancer Research, 2010, 70, 8578-8586.	0.4	25
275	Behavioral/Lifestyle and Immunologic Factors Associated with HPV Infection among Women Older Than 45 Years. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 3044-3054.	1.1	80
276	Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1954-1959.	1.1	64
277	Longitudinal Study of Human Papillomavirus Persistence and Cervical Intraepithelial Neoplasia Grade 2/3: Critical Role of Duration of Infection. Journal of the National Cancer Institute, 2010, 102, 315-324.	3.0	320
278	Human Papillomavirus Types 16 and 18 DNA Load in Relation to Coexistence of Other Types, Particularly Those in the Same Species. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2507-2512.	1.1	28
279	Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 113-120.	1.1	76
280	Common Genetic Variation in <i>TP53</i> and Risk of Human Papillomavirus Persistence and Progression to CIN3/Cancer Revisited. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1631-1637.	1.1	23
281	Screening and Prevention Methods for Cervical Cancer. JAMA - Journal of the American Medical Association, 2009, 302, 1809.	3.8	24
282	Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ: British Medical Journal, 2009, 339, b2569-b2569.	2.4	167
283	From India to the World — A Better Way to Prevent Cervical Cancer. New England Journal of Medicine, 2009, 360, 1453-1455.	13.9	51
284	Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97. Journal of Virology, 2009, 83, 1443-1455.	1.5	82
285	Relationship Between Cigarette Smoking and Human Papilloma Virus Types 16 and 18 DNA Load. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3490-3496.	1.1	89
286	Influence of Loop Electrosurgical Excision Procedure on Subsequent Acquisition of New Human Papillomavirus Infections. Journal of Infectious Diseases, 2009, 199, 1612-1620.	1.9	8
287	Detection of Precancerous Cervical Lesions Is Differential by Human Papillomavirus Type. Cancer Research, 2009, 69, 3262-3266.	0.4	56
288	Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. Gynecologic Oncology, 2009, 112, 293-299.	0.6	247

#	Article	IF	CITATIONS
289	Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. Gynecologic Oncology, 2009, 115, 493-496.	0.6	24
290	Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. International Journal of Cancer, 2009, 124, 964-969.	2.3	76
291	Neither oneâ€time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. International Journal of Cancer, 2009, 125, 1649-1656.	2.3	15
292	Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. International Journal of Cancer, 2009, 125, 2151-2158.	2.3	165
293	Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. International Journal of Cancer, 2009, 125, 2609-2613.	2.3	69
294	Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer, 2009, 4, 8.	1.2	393
295	Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncology, The, 2009, 10, 1022-1023.	5.1	44
296	Treatability by Cryotherapy in a Screen-and-Treat Strategy. Journal of Lower Genital Tract Disease, 2009, 13, 174-181.	0.9	15
297	Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2. Obstetrics and Gynecology, 2009, 113, 18-25.	1.2	321
298	The Accuracy of Colposcopic Grading for Detection of High-Grade Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 2009, 13, 137-144.	0.9	119
299	The Use of Human Papillomavirus Seroepidemiology to Inform Vaccine Policy. Sexually Transmitted Diseases, 2009, 36, 675-679.	0.8	22
300	Evaluación del riesgo como guÃa en la prevención de cáncer cervical. Journal of Lower Genital Tract Disease, 2009, 2, 5-12.	0.9	0
301	Effect of the Number of Biopsies on the Subsequent Acquisition of New Human Papillomavirus Infections. Obstetrics and Cynecology, 2009, 114, 1057-1062.	1.2	6
302	Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer, 2008, 113, 1980-1993.	2.0	121
303	Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer, 2008, 113, 3031-3035.	2.0	17
304	Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia. Vaccine, 2008, 26, K1-K16.	1.7	658
305	Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine, 2008, 26, 4795-4808.	1.7	145
306	Heterogeneity in CIN3 diagnosis. Lancet Oncology, The, 2008, 9, 404-406.	5.1	73

#	Article	IF	CITATIONS
307	Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections. Journal of the National Cancer Institute, 2008, 100, 513-517.	3.0	436
308	Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?. American Journal of Clinical Pathology, 2008, 130, 65-70.	0.4	17
309	Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study. Journal of Clinical Microbiology, 2008, 46, 109-117.	1.8	91
310	Human Papillomavirus Genotype Specificity of Hybrid Capture 2. Journal of Clinical Microbiology, 2008, 46, 2595-2604.	1.8	156
311	Comparison of Two PCR-Based Human Papillomavirus Genotyping Methods. Journal of Clinical Microbiology, 2008, 46, 3437-3445.	1.8	75
312	A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1248-1254.	1.1	60
313	Factors Influencing Histologic Confirmation of High-Grade Squamous Intraepithelial Lesion Cytology. Obstetrics and Gynecology, 2008, 112, 637-645.	1.2	17
314	An Analysis of High-Risk Human Papillomavirus DNA-Negative Cervical Precancers in the ASCUS-LSIL Triage Study (ALTS). Obstetrics and Gynecology, 2008, 111, 847-856.	1.2	44
315	Interobserver Agreement in the Assessment of Components of Colposcopic Grading. Obstetrics and Gynecology, 2008, 111, 1279-1284.	1.2	68
316	Spectroscopic Imaging as Triage Test for Cervical Disease. Journal of Lower Genital Tract Disease, 2008, 12, 52-53.	0.9	2
317	Risk Assessment to Guide the Prevention of Cervical Cancer. Journal of Lower Genital Tract Disease, 2008, 12, 1-7.	0.9	59
318	Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 11-16.	1.1	35
319	The Expanded Use of HPV Testing in Gynecologic Practice per ASCCP-Guided Management Requires the Use of Well-Validated Assays. American Journal of Clinical Pathology, 2007, 127, 335-337.	0.4	140
320	Interobserver Agreement in the Evaluation of Digitized Cervical Images. Obstetrics and Gynecology, 2007, 110, 833-840.	1.2	52
321	The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses. American Journal of Clinical Pathology, 2007, 127, 805-815.	0.4	186
322	Evaluation of a Novel PCR-Based Assay for Detection and Identification of <i>Chlamydia trachomatis</i> Serovars in Cervical Specimens. Journal of Clinical Microbiology, 2007, 45, 3986-3991.	1.8	25
323	A 2‥ear Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Lowâ€Grade Squamous Intraepithelial Lesion. Journal of Infectious Diseases, 2007, 195, 1582-1589.	1.9	365
324	Human Papillomavirus (HPV) Genotyping Using Paired Exfoliated Cervicovaginal Cells and Paraffin-Embedded Tissues To Highlight Difficulties in Attributing HPV Types to Specific Lesions. Journal of Clinical Microbiology, 2007, 45, 3245-3250.	1.8	39

#	Article	IF	CITATIONS
325	Identification and characterization of two novel human papillomaviruses (HPVs) by overlapping PCR: HPV102 and HPV106. Journal of General Virology, 2007, 88, 2952-2955.	1.3	21
326	CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3. International Journal of Gynecological Pathology, 2007, 26, 441-446.	0.9	200
327	Risk of Precancer and Follow-up Management Strategies for Women With Human Papillomavirus–Negative Atypical Squamous Cells of Undetermined Significance. Obstetrics and Gynecology, 2007, 109, 1325-1331.	1.2	57
328	Predicting Absolute Risk of Cervical Intraepithelial Neoplasia 3 during Postcolposcopic Follow-up. Journal of Lower Genital Tract Disease, 2007, 11, 64.	0.9	0
329	A Comparison of Cervical and Vaginal Human Papillomavirus. Sexually Transmitted Diseases, 2007, 34, 849-855.	0.8	73
330	Human papillomavirus and cervical cancer. Lancet, The, 2007, 370, 890-907.	6.3	2,343
331	The Natural History of Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia Among Young Women in the Guanacaste Cohort Shortly After Initiation of Sexual Life. Sexually Transmitted Diseases, 2007, 34, 494-502.	0.8	51
332	Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45. International Journal of Cancer, 2007, 121, 193-198.	2.3	16
333	High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. International Journal of Cancer, 2007, 121, 2787-2793.	2.3	134
334	Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer, 2007, 111, 145-153.	2.0	119
335	Human papillomavirus (HPV) types 101 and 103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. Virology, 2007, 360, 447-453.	1.1	58
336	Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. American Journal of Obstetrics and Gynecology, 2007, 197, 47.e1-47.e8.	0.7	62
337	Risk assessment to guide the prevention of cervical cancer. American Journal of Obstetrics and Gynecology, 2007, 197, 356.e1-356.e6.	0.7	140
338	DNA extraction: An understudied and important aspect of HPV genotyping using PCR-based methods. Journal of Virological Methods, 2007, 143, 45-54.	1.0	45
339	Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine, 2006, 24, S42-S51.	1.7	331
340	Number of Cervical Biopsies and Sensitivity of Colposcopy. Obstetrics and Gynecology, 2006, 108, 264-272.	1.2	289
341	Preparing Digitized Cervigrams for Colposcopy Research and Education: Determination of Optimal Resolution and Compression Parameters. Journal of Lower Genital Tract Disease, 2006, 10, 39-44.	0.9	11
342	Digital Tools for Collecting Data from Cervigrams for Research and Training in Colposcopy. Journal of Lower Genital Tract Disease, 2006, 10, 16-25.	0.9	46

#	Article	IF	CITATIONS
343	Cervical Tissue Collection Methods for RNA Preservation: Comparison of Snap-frozen, Ethanol-fixed, and RNAlater-fixation. Diagnostic Molecular Pathology, 2006, 15, 144-148.	2.1	41
344	Colposcopy at a crossroads. American Journal of Obstetrics and Gynecology, 2006, 195, 349-353.	0.7	178
345	Predicting absolute risk of CIN3 during post-colposcopic follow-up: Results from the ASCUS-LSIL Triage Study (ALTS). American Journal of Obstetrics and Gynecology, 2006, 195, 341-348.	0.7	68
346	The Bethesda interobserver reproducibility study (BIRST). Cancer, 2006, 111, 15-25.	2.0	72
347	When to test women for human papillomavirus. BMJ: British Medical Journal, 2006, 332, 61.	2.4	11
348	Cost-Effectiveness Analysis Based on the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). Journal of the National Cancer Institute, 2006, 98, 92-100.	3.0	89
349	Human Papillomavirus Testing Following Loop Electrosurgical Excision Procedure Identifies Women at Risk for Posttreatment Cervical Intraepithelial Neoplasia Grade 2 or 3 Disease. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 908-914.	1.1	98
350	Persistent Human Papillomavirus Infection Is Associated with a Generalized Decrease in Immune Responsiveness in Older Women. Cancer Research, 2006, 66, 11070-11076.	0.4	98
351	Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. Cancer Research, 2006, 66, 1218-1224.	0.4	95
352	Human Papillomavirus Genotypes and the Cumulative 2‥ear Risk of Cervical Precancer. Journal of Infectious Diseases, 2006, 194, 1291-1299.	1.9	120
353	Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality. Cancer Research, 2006, 66, 10112-10119.	0.4	105
354	Towards Improved Biomarker Studies of Cervical Neoplasia. Diagnostic Molecular Pathology, 2005, 14, 59-64.	2.1	5
355	The distribution of neoplasia arising on the cervix: Results from the ALTS trial. American Journal of Obstetrics and Gynecology, 2005, 193, 1331-1337.	0.7	33
356	The carcinogenicity of human papillomavirus types reflects viral evolution. Virology, 2005, 337, 76-84.	1.1	487
357	Re: Muñoz et al., "Against which human papillomavirus types shall we vaccinate and screen? The international perspective.―Int J Cancer 2004;111:278–85. International Journal of Cancer, 2005, 115, 670-670.	2.3	0
358	Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: Results from two studies conducted in Costa Rica and the United States. International Journal of Cancer, 2005, 116, 599-605.	2.3	24
359	Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in India. International Journal of Cancer, 2005, 116, 830-831.	2.3	2
360	Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. International Journal of Cancer, 2005, 117, 1007-1012.	2.3	40

#	Article	IF	CITATIONS
361	Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer, 2005, 104, 61-70.	2.0	56
362	A Comparison of a Prototype PCR Assay and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus DNA in Women With Equivocal or Mildly Abnormal Papanicolaou Smears. American Journal of Clinical Pathology, 2005, 124, 722-732.	0.4	68
363	Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. Journal of Experimental Medicine, 2005, 201, 1069-1075.	4.2	209
364	Semiquantitative Human Papillomavirus Type 16 Viral Load and the Prospective Risk of Cervical Precancer and Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1311-1314.	1.1	36
365	Medication Use, Medical Conditions, and the Risk of Human Papillomavirus Infection and Subsequent Cervical Intraepithelial Neoplasia 3 Among Women with Mild Cytologic Abnormalities. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 542-545.	1.1	3
366	Epidemiologic Profile of Typeâ€Specific Human Papillomavirus Infection and Cervical Neoplasia in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2005, 191, 1796-1807.	1.9	322
367	A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests. Journal of the National Cancer Institute, 2005, 97, 147-150.	3.0	128
368	Evaluating the Risk of Cervical Precancer with a Combination of Cytologic, Virologic, and Visual Methods. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2665-2668.	1.1	27
369	Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities. Journal of the National Cancer Institute, 2005, 97, 1066-1071.	3.0	273
370	A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa Rica. Journal of Infectious Diseases, 2005, 191, 1808-1816.	1.9	354
371	RESPONSE: Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests. Journal of the National Cancer Institute, 2005, 97, 939-941.	3.0	3
372	The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice. Journal of the National Cancer Institute, 2005, 97, 1072-1079.	3.0	921
373	The Promise of Global Cervical-Cancer Prevention. New England Journal of Medicine, 2005, 353, 2101-2104.	13.9	221
374	A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. American Journal of Clinical Pathology, 2005, 124, 722-32.	0.4	37
375	Have We Resolved How To Triage Equivocal Cervical Cytology?. Journal of the National Cancer Institute, 2004, 96, 250-251.	3.0	18
376	Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening. Obstetrics and Gynecology, 2004, 103, 304-309.	1.2	443
377	Seroreactivity to Human Papillomavirus (HPV) Types 16, 18, or 31 and Risk of Subsequent HPV Infection. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 324-327.	1.1	177
378	A Populationâ€Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. Journal of Infectious Diseases, 2004, 190, 458-467.	1.9	72

#	Article	IF	CITATIONS
379	Interlaboratory Reliability of Hybrid Capture 2. American Journal of Clinical Pathology, 2004, 122, 238-245.	0.4	99
380	Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. American Journal of Obstetrics and Gynecology, 2004, 191, 1590-1597.	0.7	31
381	Comparison of Ophthalmic Sponges for Measurements of Immune Markers from Cervical Secretions. Vaccine Journal, 2004, 11, 399-405.	3.2	33
382	Evidence-Based Screening and Management Guidelines Address the Realistic Concerns of Practicing Clinicians and Pathologists. Journal of Lower Genital Tract Disease, 2004, 8, 150-154.	0.9	3
383	Performance of Direct Visual Inspection of the Cervix with Acetic Acid and Magnification in a Previously Screened Population. Journal of Lower Genital Tract Disease, 2004, 8, 132-138.	0.9	7
384	Interlaboratory reliability of Hybrid Capture 2. American Journal of Clinical Pathology, 2004, 122, 238-45.	0.4	59
385	Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10 000 women in Guanacaste, Costa Rica. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2004, 15, 75-89.	0.6	74
386	Correlates of IL-10 and IL-12 concentrations in cervical secretions. Journal of Clinical Immunology, 2003, 23, 175-183.	2.0	39
387	Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA–positive atypical squamous cells of undetermined significance: A two-year prospective study. American Journal of Obstetrics and Gynecology, 2003, 188, 1401-1405.	0.7	184
388	Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. American Journal of Obstetrics and Gynecology, 2003, 188, 1406-1412.	0.7	331
389	Stability of archived liquid-based cytologic specimens. Cancer, 2003, 99, 320-322.	2.0	8
390	Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer. Journal of Clinical Microbiology, 2003, 41, 4022-4030.	1.8	55
391	Adding a Test for Human Papillomavirus DNA to Cervical-Cancer Screening. New England Journal of Medicine, 2003, 348, 489-490.	13.9	229
392	Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis. Journal of the National Cancer Institute, 2003, 95, 46-52.	3.0	386
393	Right-Sided Ectocervical Lesions May Be Associated with False-Negative Cytology Among Women with Histologic Cervical Intraepithelial Neoplasia 2 or 3. Journal of Lower Genital Tract Disease, 2003, 7, 175-183.	0.9	2
394	Chapter 2: Natural History of Anogenital Human Papillomavirus Infection and Neoplasia. Journal of the National Cancer Institute Monographs, 2003, 2003, 14-19.	0.9	383
395	Human Papillomavirus: Epidemiology and Public Health. Archives of Pathology and Laboratory Medicine, 2003, 127, 930-934.	1.2	240
396	Findings to Date From the ASCUS-LSIL Triage Study (ALTS). Archives of Pathology and Laboratory Medicine, 2003, 127, 946-949.	1.2	186

#	Article	IF	CITATIONS
397	Enhanced Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Virus-Like Particles of Human Papillomavirus. Journal of Clinical Microbiology, 2002, 40, 1755-1760.	1.8	63
398	A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women. Journal of the National Cancer Institute, 2002, 94, 1406-1414.	3.0	208
399	Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible. Journal of Clinical Microbiology, 2002, 40, 1088-1090.	1.8	70
400	Effects of Age and Human Papilloma Viral Load on Colposcopy Triage: Data From the Randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). Journal of the National Cancer Institute, 2002, 94, 102-107.	3.0	245
401	Sexual Behavior, Human Papillomavirus Type 16 (HPV 16) Infection, and HPV 16 Seropositivity. Sexually Transmitted Diseases, 2002, 29, 182-187.	0.8	34
402	Human Papillomavirus DNA Remains Detectable Longer than Related Cervical Cytologic Abnormalities. Journal of Infectious Diseases, 2002, 186, 1169-1172.	1.9	29
403	Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet, The, 2002, 360, 228-229.	6.3	222
404	ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary. Obstetrics and Gynecology, 2002, 99, 671-674.	1.2	21
405	Can cervicography be improved? An evaluation with arbitrated cervicography interpretations. American Journal of Obstetrics and Gynecology, 2002, 187, 15-23.	0.7	22
406	Comparisons of HPV DNA detection by MY09/11 PCR methods. Journal of Medical Virology, 2002, 68, 417-423.	2.5	158
407	Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. International Journal of Cancer, 2002, 102, 172-178.	2.3	94
408	Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United Kingdom. Cancer, 2002, 96, 14-20.	2.0	45
409	Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer, 2002, 95, 2145-2151.	2.0	84
410	Response 4. Journal of Lower Genital Tract Disease, 2002, 6, 50-52.	0.9	0
411	Cervicography for Triage of Women With Mildly Abnormal Cervical Cytology Results. Obstetrical and Gynecological Survey, 2002, 57, 86-87.	0.2	0
412	Cervicography for triage of women with mildly abnormal cervical cytology results. American Journal of Obstetrics and Gynecology, 2001, 185, 939-943.	0.7	19
413	Cervical HPV DNA Detection as a Predictor of a Recurrent SIL Diagnosis Among Untreated Women. Journal of Lower Genital Tract Disease, 2001, 5, 138-143.	0.9	1
414	Qualification of ASCUS. American Journal of Clinical Pathology, 2001, 116, 386-394.	0.4	157

#	Article	IF	CITATIONS
415	Comparison of Three Management Strategies for Patients With Atypical Squamous Cells of Undetermined Significance: Baseline Results From a Randomized Trial. Journal of the National Cancer Institute, 2001, 93, 293-299.	3.0	919
416	A Prospective Study of Human Papillomavirus (HPV) Type 16 DNA Detection by Polymerase Chain Reaction and Its Association with Acquisition and Persistence of Other HPV Types. Journal of Infectious Diseases, 2001, 183, 8-15.	1.9	242
417	Author reply. , 2000, 90, 67-69.		3
418	Review of the Bethesda System atlas does not improve reproducibility or accuracy in the classification of atypical squamous cells of undetermined significance smears. Cancer, 2000, 90, 201-206.	2.0	35
419	Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors. American Journal of Obstetrics and Gynecology, 2000, 183, 1232-1237.	0.7	45
420	ASCUS-LSIL Triage Study. Acta Cytologica, 2000, 44, 726-742.	0.7	234
421	HPV DNA Testing in Cervical Cancer Screening. JAMA - Journal of the American Medical Association, 2000, 283, 87.	3.8	466
422	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. Journal of the National Cancer Institute, 2000, 92, 464-474.	3.0	515
423	Detection of Human Papillomavirus DNA in Cytologically Normal Women and Subsequent Cervical Squamous Intraepithelial Lesions. Journal of the National Cancer Institute, 1999, 91, 954-960.	3.0	225
424	Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. Journal of Immunological Methods, 1999, 225, 131-143.	0.6	47
425	Cervicography screening for cervical cancer among 8460 women in a high-risk population. American Journal of Obstetrics and Gynecology, 1999, 180, 290-298.	0.7	56
426	Risk factors for rapid-onset cervical cancer. American Journal of Obstetrics and Gynecology, 1999, 180, 571-577.	0.7	117
427	Epidemiologic determinants of vaginal pH. American Journal of Obstetrics and Gynecology, 1999, 180, 1060-1066.	0.7	52
428	Utility of liquid-based cytology for cervical carcinoma screening. , 1999, 87, 48-55.		199
429	A Prospective Study of Biopsy-Confirmed Cervical Intraepithelial Neoplasia Grade 1. Journal of Lower Genital Tract Disease, 1999, 3, 104-110.	0.9	6
430	p53 polymorphism and risk of cervical cancer. Nature, 1998, 396, 531-532.	13.7	105
431	Why, How, and When the Cytological Diagnosis of ASCUS Should Be Eliminated. Journal of Lower Genital Tract Disease, 1998, 2, 165-169.	0.9	7
432	Diagnostic certainty in pancreatic cancer. Journal of Clinical Epidemiology, 1996, 49, 601-602.	2.4	26

#	Article	IF	CITATIONS
433	Serum Antibodies to HPV 16 Virus-Like Particles Are Not Associated with Penile Cancer in Chinese Males. Viral Immunology, 1996, 9, 23-25.	0.6	9
434	Laboratory and epidemiologic studies of fecapentaenes. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1991, 259, 387-397.	1.2	19